Kin Meds

1. 3. Kin Meds handles the clinical review for branded GLP-1 options; the current page directs fulfillment and medication pricing to NovoCare Pharmacy or LillyDirect. The older $149 figure is not a verified drug price or current additional membership charge. The page states no automatic subscription. Confirm the actual consultation charge, manufacturer invoice and order-cancellation terms before beginning. The FAQ explicitly states no membership fee. Rush and Strive are named pharmacy partners; the assigned dispenser remains unconfirmed. Care is advertised nationwide with treatment-specific restrictions, and a live visit may be required in some states. Orders cannot be changed or canceled once processing starts.

September 2026

1. 4. The branded-medications page is a near-exact match for the brief's membership-trap example: each drug card ('Wegovy® Injection', 'Wegovy® Pill', 'Zepbound®', 'Foundayo®', 'Zepbound® Vial') shows 'Starting at $149' with a footnote '* $149 for the provider consultation and follow ups only. Price of the medication(s) are charged upon consult approval.' The comparison table separately shows 'Kin Med's Membership Fee $149/mo' AND 'Prescription Medication (Paid Only if Approved) From $149/mo' as two distinct line items that happen to share the same number -- both were recorded but are NOT the same charge. The 'Personalized GLP-1' ($199) vs 'Personalized GLP-1/GIP+B12' ($249) compounded product classification into semaglutide vs tirzepatide is inferred from page naming (GIP dual-agonist mechanism = tirzepatide), since the site's own footer disclaimer says formulations may contain 'Semaglutide or Tirzepatide' determined by the prescribing provider -- treat the semaglutide/tirzepatide split with some caution.